REA
A multifusion protein-based vaccine formulated with MPL/DDA.
Read MoreNETB-EA
The Khader Lab in collaboration with EclipTB Inc andBlueWillow Biologics Inc., have developed an intranasal booster sub-unit, mucosal vaccine comprising of Mtb immunodominant antigens Early secreted antigenic target 6 kDa andAntigen 85B together with nanoemulsion adjuvant NE01-NETB-EA.
Read MorepcDNA3.1-rpfB, pcDNA3.1-rpfD
The candidate vaccine we are developing is a recombinant plasmid DNA vaccine. Two genes from the rpfs family, namely rpfB and rpfD, were inserted full-length into the pcDNA3.1 plasmid along with the Kozak sequence, resulting in recombinant plasmids pcDNA3.1-rpfB and pcDNA3.1-rpfD. The vaccination method used on test animals is intramuscular injection of the recombinant plasmid…
Read MoreTBvac-1, TBvac-2, TBvac-10
TBvac-1, TBvac-2, and TBvac-10 use a recombinant tri-segmented Pichinde virus (PICV) vector (rP18tri) to express M. tuberculosis antigens. TBvac-1 and TBvac-2 encode Ag85B, EsxA/ESAT-6, and EsxH/TB10.4, with antigen locations swapped between S1 and S2 segments. TBvac-10 encodes Ag85B, EsxH/TB10.4, RpfA, and Rv1733c. Vaccine stocks are produced in BHK-21 cells from plaque purified virus.
Read MoreBCG-EVs
This vaccine comprises EVs derived from Mycobacterium bovis and Escherichia coli Nissle 1917. BCG-EVs carry multiple molecules, including known protective TB antigens. The EVs will be lyophilized to ensure physicochemical stability and eliminate the need for a cold chain. Owing to their acellular nature, the vaccine is suitable for infants and children, including those living…
Read More